image
Dyne Therapeutics, Inc. DYN
Healthcare - Biotechnology - NASDAQ - US
Watchlist
$ 8.76
-2.01 %
$ 996 M
Market Cap
-2.43
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one DYN stock under the worst case scenario is HIDDEN Compared to the current market price of 8.76 USD, Dyne Therapeutics, Inc. is HIDDEN

DYN Intrinsic Value
HIDDEN
SHOW

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one DYN stock under the base case scenario is HIDDEN Compared to the current market price of 8.76 USD, Dyne Therapeutics, Inc. is HIDDEN

DYN Intrinsic Value
HIDDEN
SHOW

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one DYN stock under the best case scenario is HIDDEN Compared to the current market price of 8.76 USD, Dyne Therapeutics, Inc. is HIDDEN

DYN Intrinsic Value
HIDDEN
SHOW
2. FUNDAMENTAL ANALYSIS

Price Chart DYN

image
1M -68%
6M -183%
1Y -325%
3Y -3%
5Y --%
All
$17.0$17.0$16.0$16.0$15.0$15.0$14.0$14.0$13.0$13.0$12.0$12.0$11.0$11.0$10.0$10.0$9.0$9.0$8.0$8.0$7.0$7.0$6.0$6.015 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '2515 Jun15 JunJul '25Jul '25
FINANCIALS
0 REVENUE
0.00%
Growth Rates
1Year 0.00%
3Years 0.00%
5Years 0.00%
7Years 0.00%
10Years 0.00%
-344 M OPERATING INCOME
-42.01%
Growth Rates
1Year -42.01%
3Years -31.85%
5Years -90.17%
7Years 2.55%
10Years -0.79%
-317 M NET INCOME
-34.54%
Growth Rates
1Year -34.54%
3Years -28.59%
5Years -84.47%
7Years -26.48%
10Years -16.83%
-292 M OPERATING CASH FLOW
-55.38%
Growth Rates
1Year -55.38%
3Years -34.72%
5Years -89.92%
7Years -5.96%
10Years -16.78%
-204 M INVESTING CASH FLOW
-244.96%
Growth Rates
1Year -244.96%
3Years -13.96%
5Years -162.19%
7Years 31.07%
10Years 27.59%
810 M FINANCING CASH FLOW
1390.92%
Growth Rates
1Year 1390.92%
3Years 72.49%
5Years 109.67%
7Years 14.77%
10Years -16.98%
0 REVENUE
0.00%
Growth Rates
1Year 0.00%
3Years 0.00%
5Years 0.00%
7Years 0.00%
10Years 0.00%
-122 M OPERATING INCOME
-26.02%
Growth Rates
1Year -42.01%
3Years -31.85%
5Years -90.17%
7Years 2.55%
10Years -0.79%
-115 M NET INCOME
-28.83%
Growth Rates
1Year -34.54%
3Years -28.59%
5Years -84.47%
7Years -26.48%
10Years -16.83%
-106 M OPERATING CASH FLOW
-25.56%
Growth Rates
1Year -55.38%
3Years -34.72%
5Years -89.92%
7Years -5.96%
10Years -16.78%
1.46 M INVESTING CASH FLOW
109.11%
Growth Rates
1Year -244.96%
3Years -13.96%
5Years -162.19%
7Years 31.07%
10Years 27.59%
141 M FINANCING CASH FLOW
3784.52%
Growth Rates
1Year 1390.92%
3Years 72.49%
5Years 109.67%
7Years 14.77%
10Years -16.98%
Balance Sheet Dyne Therapeutics, Inc.
image
Current Assets 659 M
Cash & Short-Term Investments 642 M
Receivables 0
Other Current Assets 17 M
Non-Current Assets 32 M
Long-Term Investments 0
PP&E 30 M
Other Non-Current Assets 1.94 M
92.92 %4.34 %Total Assets$691.2m
Current Liabilities 42.3 M
Accounts Payable 6.56 M
Short-Term Debt 4.85 M
Other Current Liabilities 30.8 M
Non-Current Liabilities 19.1 M
Long-Term Debt 19.1 M
Other Non-Current Liabilities 0
10.69 %7.90 %50.24 %31.17 %Total Liabilities$61.4m
EFFICIENCY
Earnings Waterfall Dyne Therapeutics, Inc.
image
Revenue 0
Cost Of Revenue 0
Gross Profit 0
Operating Expenses 344 M
Operating Income -344 M
Other Expenses -26.5 M
Net Income -317 M
00(50m)(50m)(100m)(100m)(150m)(150m)(200m)(200m)(250m)(250m)(300m)(300m)(350m)(350m)000(344m)(344m)26m(317m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
0.00% GROSS MARGIN
0.00%
Averages
1Year 0.00%
3Years 0.00%
5Years 0.00%
7Years 0.00%
10Years -68.73%
0.00% OPERATING MARGIN
0.00%
Averages
1Year 0.00%
3Years 0.00%
5Years 0.00%
7Years 0.00%
10Years -12.07%
0.00% NET MARGIN
0.00%
Averages
1Year 0.00%
3Years 0.00%
5Years 0.00%
7Years 0.00%
10Years -6.98%
-50.40% ROE
-50.40%
Averages
1Year -50.40%
3Years -124.77%
5Years -86.40%
7Years -61.41%
10Years -48.49%
-45.92% ROA
-45.92%
Averages
1Year -45.92%
3Years -80.93%
5Years -58.90%
7Years -62.15%
10Years -44.34%
-52.60% ROIC
-52.60%
Averages
1Year -52.60%
3Years -105.02%
5Years -73.81%
7Years -74.55%
10Years -52.64%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Dyne Therapeutics, Inc.
image
400m400m300m300m200m200m100m100m00(100m)(100m)(200m)(200m)(300m)(300m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -317 M
Depreciation & Amortization -1.93 M
Capital Expenditures -2.38 M
Stock-Based Compensation 45.9 M
Change in Working Capital -19.5 M
Others -10.5 M
Free Cash Flow -295 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Dyne Therapeutics, Inc.
image
Wall Street analysts predict an average 1-year price target for DYN of $46.6 , with forecasts ranging from a low of $34 to a high of $53 .
DYN Lowest Price Target Wall Street Target
34 USD 288.13%
DYN Average Price Target Wall Street Target
46.6 USD 431.96%
DYN Highest Price Target Wall Street Target
53 USD 505.02%
Price
Max Price Target
Min Price Target
Average Price Target
555550504545404035353030252520201515101055Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26Jun '26Jun '26Jul '26Jul '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 8
6. Ownership
Insider Ownership Dyne Therapeutics, Inc.
image
Sold
0-3 MONTHS
74.1 K USD 3
3-6 MONTHS
200 K USD 5
6-9 MONTHS
14.5 M USD 5
9-12 MONTHS
97 M USD 6
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
264 K USD 1
9-12 MONTHS
7. News
Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares WALTHAM, Mass., July 02, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq:DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced the closing of its previously announced underwritten public offering of 27,878,788 shares of its common stock at a public offering price of $8.25 per share, which includes 3,636,363 shares issued upon the exercise in full by the underwriters of their option to purchase additional shares of common stock in the offering. The gross proceeds to Dyne from the offering were approximately $230.0 million, before deducting underwriting discounts and commissions and offering expenses payable by Dyne. All of the shares in the offering were sold by Dyne. globenewswire.com - 6 days ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN NEW YORK , July 2, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Dyne Therapeutics, Inc. ("Dyne" or the "Company") (NASDAQ: DYN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. prnewswire.com - 1 week ago
Tesla, Progress Software, Dyne Therapeutics And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session U.S. stock futures were lower this morning, with the Dow futures falling around 0.1% on Tuesday. benzinga.com - 1 week ago
Dyne Therapeutics Announces Pricing of $200.0 Million Public Offering of Common Stock WALTHAM, Mass., June 30, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced the pricing of an underwritten public offering of 24,242,425 shares of its common stock at a public offering price of $8.25 per share. The gross proceeds to Dyne from the offering, before deducting underwriting discounts and commissions and offering expenses payable by Dyne, are expected to be $200.0 million. All shares in the offering are being sold by Dyne. The offering is expected to close on or about July 2, 2025, subject to customary closing conditions. In addition, Dyne has granted the underwriters a 30-day option to purchase up to an additional 3,636,363 shares of its common stock at the public offering price, less the underwriting discounts and commissions. globenewswire.com - 1 week ago
Dyne Therapeutics Announces Proposed Public Offering of Common Stock WALTHAM, Mass., June 30, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that it has commenced an underwritten public offering of $200,000,000 of shares of its common stock. Dyne also intends to grant the underwriters a 30-day option to purchase up to an additional $30,000,000 of shares of its common stock. All of the shares in the proposed offering are to be sold by Dyne. globenewswire.com - 1 week ago
Dyne Therapeutics Secures Up to $275 Million in Debt Financing from Hercules Capital - $100 million funded upfront; additional $175 million tied to milestones  provides strategic flexibility through key inflection points - globenewswire.com - 1 week ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN NEW YORK , June 27, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Dyne Therapeutics, Inc. ("Dyne" or the "Company") (NASDAQ: DYN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. prnewswire.com - 1 week ago
Dyne Therapeutics Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - DYN LOS ANGELES , June 24, 2025 /PRNewswire/ -- The DJS Law Group announces that it is investigating claims on behalf of investors of Dyne Therapeutics ("Dyne" or "the Company") (NASDAQ: DYN) for violations of the securities laws. INVESTIGATION DETAILS: The investigation focuses on whether the Company issued misleading statements and/or failed to disclose information pertinent to investors. prnewswire.com - 2 weeks ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Dyne Therapeutics, Inc. – DYN NEW YORK, June 23, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Dyne Therapeutics, Inc. (“Dyne” or the “Company”) (NASDAQ: DYN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. globenewswire.com - 2 weeks ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN NEW YORK , June 22, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Dyne Therapeutics, Inc. ("Dyne" or the "Company") (NASDAQ: DYN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. prnewswire.com - 2 weeks ago
Dyne Therapeutics - Emergence As A Superior DM1 / DMD Player Warrants Rating Upgrade Upgrading Dyne Therapeutics to 'Buy' due to promising late-stage DM1 and DMD drug candidates and significant unmet need in both indications. Recent management changes and a more measured clinical approach improve confidence in Dyne's ability to deliver safe, effective therapies. Key data catalysts for DYNE-251 and DYNE-101 are expected in late 2025 and H1 2026, with potential accelerated approval submissions by late 2026. seekingalpha.com - 2 weeks ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN NEW YORK, June 18, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Dyne Therapeutics, Inc. (“Dyne” or the “Company”) (NASDAQ: DYN). Such investors are advised to contact Danielle Peyton at  newaction@pomlaw.com  or 646-581-9980, ext. 7980. globenewswire.com - 2 weeks ago
8. Profile Summary

Dyne Therapeutics, Inc. DYN

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 996 M
Dividend Yield 0.00%
Description Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was incorporated in 2017 and is headquartered in Waltham, Massachusetts..
Contact 1560 Trapelo Road, Waltham, MA, 02451 https://www.dyne-tx.com
IPO Date Sept. 17, 2020
Employees 192
Officers Dr. Oxana Beskrovnaya Ph.D. Chief Innovation Officer Dr. Ranjan Batra Ph.D. Chief Scientific Officer Ms. Johanna Friedl-Naderer Chief Commercial Officer Mr. Daniel Wilson Senior Vice President & Head of Legal Mr. John G. Cox M.B.A. Chief Executive Officer, President & Director Dr. Douglas Kerr M.B.A., M.D., Ph.D. Chief Medical Officer Mr. Erick J. Lucera C.F.A., CPA Chief Financial Officer, Principal Financial Officer & Principal Accounting Officer and Treasurer Mr. James P. Bilotta M.B.A. Chief Digital & Information Officer Ms. Lucia Celona Chief Human Resource Officer Dr. Rajesh Manchanda Ph.D. Chief Technical Officer